<p>重新调度与 Avicanna 已建立的制药和医疗大麻战略相一致</p>
<p>重新调度进一步支持研发、临床开发和医疗事务计划的推进</p>
<p>多伦多，2026 年 4 月 28 日（环球新闻）—— Avicanna Inc.（“Avicanna” 或 “公司”）（TSX：AVCN）（OTCQX：AVCNF）（FSE：0NN），一家专注于植物来源的基于大麻素的产品的开发、制造和商业化的生物制药公司，欢迎美国司法部和美国缉毒局宣布将某些基于大麻素的产品从美国联邦《受控物质法》第 I 类重新分类为第 III 类，这一举措是为了落实特朗普总统于 2025 年 12 月 18 日发布的行政命令。公司对此发展表示赞赏，认为这是推进科学研究、改善监管透明度和扩大患者获取的重要一步。公司很高兴提供其科学、研发、临床开发和医疗事务计划的最新进展，同时继续评估在美国的战略机会。</p>
<p><strong>管理层评论</strong></p>
<p>“我们对当前美国政府在基于大麻素的产品方面采取的行动和公告感到鼓舞，” Avicanna 首席执行官 Aras Azadian 表示。“这一里程碑强调了严格科学发展的重要性，并与 Avicanna 长期以来推进药品级大麻素产品与标准化医疗大麻平台的战略紧密相连。随着监管环境的演变，我们相信 Avicanna 在利用其知识产权组合、产品管道和垂直整合能力方面处于良好位置，以支持我们在美国市场参与的战略路线图。”</p>
<p><strong>科学和医疗亮点（2026 年迄今）</strong></p>
<p><strong>临床开发：</strong></p>
<p>Avicanna 继续推进一项强有力的临床开发战略，支持真实世界证据和随机对照试验。</p>
<ul>
<li>一项正在进行的真实世界证据研究评估医生授权的医疗大麻，已发布的研究结果显示在疼痛相关结果、心理健康指标和生活质量方面有所改善（《加拿大疼痛杂志》）。</li>
<li>与卡尔加里大学卡明医学院合作启动了一项 I 期随机、双盲、安慰剂对照的剂量寻找研究，评估口服 THC 对焦虑和压力的剂量依赖性影响，使用 Avicanna 的专有胶囊配方。</li>
<li>在之前宣布的 II 期随机对照试验中取得进展，评估基于大麻素的配方用于关节炎疼痛，初步患者入组于 2026 年初开始。</li>
</ul>
<p><strong>研发</strong></p>
<p>公司在其专有研发管道中继续取得重要进展。继续推进、商业化和优化 Avicanna 的专有递送技术，包括支持制药和医疗大麻应用的 QUIX™快速起效纳米技术平台。</p>
<p><strong>医疗事务和科学参与</strong></p>
<p>Avicanna 继续通过针对性的教育和合作扩大与医疗专业人士的互动，包括 Avicenna Academy 的增长，支持基于证据的临床决策，同时通过 MyMedi.ca 平台增强患者获取，提供药剂师主导的支持计划、报销倡议和专业护理路径。公司最近宣布将举办第六届年度大麻素治疗临床研讨会，这是一个领先的临床对话、患者结果和新兴治疗应用的论坛，将以扩展的两天形式举行，既有面对面也有虚拟形式，汇聚临床医生、研究人员和关键利益相关者。</p>
<p><strong>战略展望</strong></p>
<p>不断发展的美国监管框架代表了将基于大麻素的治疗整合到制药框架中的一个重要里程碑。Avicanna 将继续监测监管发展，并评估利用其科学平台、专有配方和临床数据支持未来进入美国市场的途径，重点关注：</p>
<ul>
<li>制药开发和与 FDA 对接的路径，包括在美国的临床开发</li>
<li>以证据为驱动的联邦或州级医疗大麻模型</li>
<li>战略合作伙伴关系和许可机会</li>
</ul>
<p><strong>关于 Avicanna Inc</strong></p>
<p>Avicanna 是一家商业阶段的国际生物制药公司，专注于基于大麻素的产品和配方在全球医疗和制药市场领域的推进和商业化。Avicanna 拥有一个成熟的科学平台，包括研发和临床开发，已商业化超过三十种专有的、基于证据的成品，并支持四个商业阶段的业务支柱。</p>
<ul>
<li><strong>医疗大麻配方（RHO Phyto™）：</strong> 该配方提供多种专有产品，包括口服、舌下、外用和透皮给药，具有不同的 cannabinoids 比例，并通过持续的患者和医疗社区教育进行支持。RHO Phyto 是加拿大一个成熟的品牌，目前在多个渠道全国范围内提供，并正在扩展到新的国际市场。</li>
<li><strong>医疗大麻护理平台（MyMedi.ca）：</strong> MyMedi.ca 是一个医疗大麻护理平台，旨在更好地满足医疗大麻患者的需求，提升医疗大麻患者的体验。MyMedi.ca 由 Northern Green Canada Inc. 运营，拥有多样化的产品组合和双语药剂师主导的患者支持项目。MyMedi.ca 还为特定患者群体（如退伍军人）提供专业服务，并与公共和私人支付方合作进行审查和报销。MyMedi.ca 向医疗社区提供教育资源，以促进医疗大麻纳入医疗保健方案。</li>
<li><strong>制药管道：</strong> 利用 Avicanna 的科学平台、垂直整合和真实世界证据，Avicanna 开发了一系列专有的、针对特定适应症的基于 cannabinoids 的候选药物，这些药物处于不同的临床开发阶段。这些基于 cannabinoids 的候选药物旨在解决皮肤科、慢性疼痛和各种神经系统疾病等领域的未满足需求。</li>
<li><strong>活性药物成分（Aureus Santa Marta™）：</strong> 由公司控股子公司 Santa Marta Golden Hemp SAS（“SMGH”）提供的活性药物成分是一个商业阶段的业务，致力于为公司的国际合作伙伴提供各种高质量的 CBD、THC 和 CBG，用于食品、化妆品、医疗和制药产品的开发和生产。SMGH 也是公司供应链的一部分，是其全球消费零售、医疗大麻和制药产品可靠的输入产品来源。</li>
</ul>
<p><strong>来源 Avicanna Inc</strong>。</p>
<p><strong>保持联系</strong></p>
<p>有关 Avicanna 的更多信息，请访问我们的网站或通过电子邮件联系 Ivana Maric，邮箱为 ir@avicanna.com。</p>
<p><strong>关于前瞻性信息和声明的警示说明</strong></p>
<p>本新闻稿包含适用证券法意义上的 “前瞻性信息”。本新闻稿中包含的前瞻性信息可通过使用 “可能”、“将”、“可以”、“很可能”、“期待”、“预期”、“相信”、“打算”、“计划”、“预测”、“项目”、“估计”、“展望” 等类似表达来识别。新闻稿中包含的前瞻性信息包括但不限于关于公司未来业务运营、管理层的意见或信念以及未来业务目标的声明。尽管公司相信这些前瞻性信息所基于的期望和假设是合理的，但不应过度依赖这些前瞻性信息，因为公司无法保证它们将被证明是正确的。实际结果和发展可能与这些声明所设想的有实质性差异。前瞻性信息受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际事件或结果与前瞻性信息中预测的有实质性差异。这些风险和不确定性包括但不限于当前和未来的市场条件，包括公司普通股的市场价格，以及在公司于 2026 年 3 月 31 日提交给加拿大证券监管机构的年度信息表中列出的风险因素，该信息表可在公司在 SEDAR+ 上的资料中找到，网址为 www.sedarplus.ca。本文中的声明截至本发布之日。公司不承担更新任何前瞻性信息的意图或义务，无论是由于新信息、未来事件或结果，还是其他原因，除非适用证券法要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjd09ERTJNeU0zTlRZNU16YzJJekl5TURFME5qYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjd09ERTJNeU0zTlRZNU16YzJJekl5TURFME5qYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGY0N2Y0ZTQtZjIxNy00NTZkLTk2OGMtMWU4ZjM3MGYxZDc5LTEyMTMwMjAtMjAyNi0wNC0yOC1lbg==/tiny/Avicanna-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGY0N2Y0ZTQtZjIxNy00NTZkLTk2OGMtMWU4ZjM3MGYxZDc5LTEyMTMwMjAtMjAyNi0wNC0yOC1lbg==/tiny/Avicanna-Inc-.png"/></p>

大麻 ETF - Cambria

美国制药 ETF - iShares

另类收益 ETF -ETFMG

纯美国大麻 ETF

Seymour大麻 ETF - Amplify

WEED

<p>Avicanna Inc. 欢迎美国司法部将某些基于大麻素的产品从第一类药物重新分类为第三类药物的决定，这与其制药战略相一致。这一变化预计将增强研发、临床开发和患者获取。该公司正在推进其临床试验，包括针对焦虑和疼痛管理的 THC 研究。Avicanna 继续扩展其医疗大麻计划，并且在利用其知识产权进入未来美国市场方面处于良好位置，专注于制药开发和战略合作伙伴关系</p>

<p>Rescheduling aligns with Avicanna’s established pharmaceutical and medical cannabis strategy</p>
<div class="lb-trans"><p>重新调度与 Avicanna 已建立的制药和医疗大麻战略相一致</p>
</div><p>Rescheduling further supports advancement of R&amp;D, clinical development, and medical affairs initiatives</p>
<div class="lb-trans"><p>重新调度进一步支持研发、临床开发和医疗事务计划的推进</p>
</div><p>TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, applauds the announcement by the U.S. Department of Justice and U.S. Drug Enforcement Administration to reschedule certain cannabinoid-based products from Schedule I to Schedule III under the U.S. federal Controlled Substances Act, in furtherance of President Trumps Executive Order of December 18, 2025. The Company applauds this development as a meaningful step towards advancing scientific research, improving regulatory clarity, and expanding patient access. The Company is pleased to provide an update of its scientific, R&amp;D, clinical development, and medical affairs initiatives and programs, while continuing to evaluate strategic opportunities in the U.S.</p>
<div class="lb-trans"><p>多伦多，2026 年 4 月 28 日（环球新闻）—— Avicanna Inc.（“Avicanna” 或 “公司”）（TSX：AVCN）（OTCQX：AVCNF）（FSE：0NN），一家专注于植物来源的基于大麻素的产品的开发、制造和商业化的生物制药公司，欢迎美国司法部和美国缉毒局宣布将某些基于大麻素的产品从美国联邦《受控物质法》第 I 类重新分类为第 III 类，这一举措是为了落实特朗普总统于 2025 年 12 月 18 日发布的行政命令。公司对此发展表示赞赏，认为这是推进科学研究、改善监管透明度和扩大患者获取的重要一步。公司很高兴提供其科学、研发、临床开发和医疗事务计划的最新进展，同时继续评估在美国的战略机会。</p>
</div><p><strong>Management Commentary</strong></p>
<div class="lb-trans"><p><strong>管理层评论</strong></p>
</div><p>“We are encouraged by actions and announcements of the current U.S. Administration toward a more evidence-based and pragmatic framework for cannabinoid-based products” said Aras Azadian, Chief Executive Officer of Avicanna. “This milestone reinforces the importance of rigorous scientific development and aligns closely with Avicanna’s long-standing strategy of advancing pharmaceutical-grade cannabinoid products alongside standardized medical cannabis platforms. As the regulatory landscape evolves, we believe Avicanna is well positioned to leverage its intellectual property portfolio, pipeline, and vertically integrated capabilities to support our strategic roadmap toward participation in the U.S.”</p>
<div class="lb-trans"><p>“我们对当前美国政府在基于大麻素的产品方面采取的行动和公告感到鼓舞，” Avicanna 首席执行官 Aras Azadian 表示。“这一里程碑强调了严格科学发展的重要性，并与 Avicanna 长期以来推进药品级大麻素产品与标准化医疗大麻平台的战略紧密相连。随着监管环境的演变，我们相信 Avicanna 在利用其知识产权组合、产品管道和垂直整合能力方面处于良好位置，以支持我们在美国市场参与的战略路线图。”</p>
</div><p><strong>Scientific and Medical Highlights (2026 YTD)</strong></p>
<div class="lb-trans"><p><strong>科学和医疗亮点（2026 年迄今）</strong></p>
</div><p><strong>Clinical Development:</strong></p>
<div class="lb-trans"><p><strong>临床开发：</strong></p>
</div><p>Avicanna continues to advance a robust clinical development strategy supported by both real-world evidence and randomized controlled trials.</p>
<div class="lb-trans"><p>Avicanna 继续推进一项强有力的临床开发战略，支持真实世界证据和随机对照试验。</p>
</div><ul>
<li>An ongoing real-world evidence study evaluating physician-authorized medical cannabis has published findings demonstrating improvements in pain-related outcomes, mental health measures, and quality of life (Canadian Journal of Pain).</li>
<li>Initiation of a Phase I randomized, double-blind, placebo-controlled dose-finding study in collaboration with the University of Calgary’s Cumming School of Medicine, evaluating dose-dependent effects of oral THC on anxiety and stress using Avicanna’s proprietary capsule formulations.</li>
<li>Progress in a previously announced Phase II randomized controlled trial evaluating cannabinoid-based formulations for arthritic pain, initial patient enrollment commenced in early 2026.</li>
</ul>
<div class="lb-trans"><ul>
<li>一项正在进行的真实世界证据研究评估医生授权的医疗大麻，已发布的研究结果显示在疼痛相关结果、心理健康指标和生活质量方面有所改善（《加拿大疼痛杂志》）。</li>
<li>与卡尔加里大学卡明医学院合作启动了一项 I 期随机、双盲、安慰剂对照的剂量寻找研究，评估口服 THC 对焦虑和压力的剂量依赖性影响，使用 Avicanna 的专有胶囊配方。</li>
<li>在之前宣布的 II 期随机对照试验中取得进展，评估基于大麻素的配方用于关节炎疼痛，初步患者入组于 2026 年初开始。</li>
</ul>
</div><p><strong>Research &amp; Development</strong></p>
<div class="lb-trans"><p><strong>研发</strong></p>
</div><p>The Company continues to make meaningful progress across its proprietary R&amp;D pipeline.Continued advancement, commercialization, and optimization of Avicanna’s proprietary delivery technologies, including the QUIX™ rapid onset nanotechnology platform, supporting both pharmaceutical and medical cannabis applications.</p>
<div class="lb-trans"><p>公司在其专有研发管道中继续取得重要进展。继续推进、商业化和优化 Avicanna 的专有递送技术，包括支持制药和医疗大麻应用的 QUIX™快速起效纳米技术平台。</p>
</div><p><strong>Medical Affairs and Scientific Engagement</strong></p>
<div class="lb-trans"><p><strong>医疗事务和科学参与</strong></p>
</div><p>Avicanna continues to expand engagement with healthcare professionals through targeted education and collaboration, including the growth of Avicenna Academy, which supports evidence-based clinical decision-making, alongside the MyMedi.ca platform, which enhances patient access through pharmacist-led support programs, reimbursement initiatives, and specialized care pathways. The Company recently announced its 6th Annual Clinical Symposium on Cannabinoid Therapeutics, a leading forum for clinical dialogue, patient outcomes, and emerging therapeutic applications, to be held in an expanded two-day format, both in-person and virtually, bringing together clinicians, researchers, and key stakeholders.</p>
<div class="lb-trans"><p>Avicanna 继续通过针对性的教育和合作扩大与医疗专业人士的互动，包括 Avicenna Academy 的增长，支持基于证据的临床决策，同时通过 MyMedi.ca 平台增强患者获取，提供药剂师主导的支持计划、报销倡议和专业护理路径。公司最近宣布将举办第六届年度大麻素治疗临床研讨会，这是一个领先的临床对话、患者结果和新兴治疗应用的论坛，将以扩展的两天形式举行，既有面对面也有虚拟形式，汇聚临床医生、研究人员和关键利益相关者。</p>
</div><p><strong>Strategic Outlook</strong></p>
<div class="lb-trans"><p><strong>战略展望</strong></p>
</div><p>The evolving U.S. regulatory framework represents a significant milestone in the integration of cannabinoid-based therapeutics within a pharmaceutical framework. Avicanna will continue to monitor regulatory developments and assess pathways to leverage its scientific platform, proprietary formulations, and clinical data in support of future U.S. market entry, with a focus on:</p>
<div class="lb-trans"><p>不断发展的美国监管框架代表了将基于大麻素的治疗整合到制药框架中的一个重要里程碑。Avicanna 将继续监测监管发展，并评估利用其科学平台、专有配方和临床数据支持未来进入美国市场的途径，重点关注：</p>
</div><ul>
<li>Pharmaceutical development and FDA-aligned pathways including clinical development in the US</li>
<li>Evidence-driven and Federal or State level medical cannabis models</li>
<li>Strategic partnerships and licensing opportunities</li>
</ul>
<div class="lb-trans"><ul>
<li>制药开发和与 FDA 对接的路径，包括在美国的临床开发</li>
<li>以证据为驱动的联邦或州级医疗大麻模型</li>
<li>战略合作伙伴关系和许可机会</li>
</ul>
</div><p><strong>About Avicanna Inc</strong></p>
<div class="lb-trans"><p><strong>关于 Avicanna Inc</strong></p>
</div><p>Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&amp;D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.</p>
<div class="lb-trans"><p>Avicanna 是一家商业阶段的国际生物制药公司，专注于基于大麻素的产品和配方在全球医疗和制药市场领域的推进和商业化。Avicanna 拥有一个成熟的科学平台，包括研发和临床开发，已商业化超过三十种专有的、基于证据的成品，并支持四个商业阶段的业务支柱。</p>
</div><ul>
<li><strong>Medical Cannabis formulary (RHO Phyto™):</strong> The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.</li>
<li><strong>Medical cannabis care platform (MyMedi.ca):</strong> MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.</li>
<li><strong>Pharmaceutical pipeline:</strong> Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders.</li>
<li><strong>Active pharmaceutical ingredients (Aureus Santa Marta™):</strong> Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>医疗大麻配方（RHO Phyto™）：</strong> 该配方提供多种专有产品，包括口服、舌下、外用和透皮给药，具有不同的 cannabinoids 比例，并通过持续的患者和医疗社区教育进行支持。RHO Phyto 是加拿大一个成熟的品牌，目前在多个渠道全国范围内提供，并正在扩展到新的国际市场。</li>
<li><strong>医疗大麻护理平台（MyMedi.ca）：</strong> MyMedi.ca 是一个医疗大麻护理平台，旨在更好地满足医疗大麻患者的需求，提升医疗大麻患者的体验。MyMedi.ca 由 Northern Green Canada Inc. 运营，拥有多样化的产品组合和双语药剂师主导的患者支持项目。MyMedi.ca 还为特定患者群体（如退伍军人）提供专业服务，并与公共和私人支付方合作进行审查和报销。MyMedi.ca 向医疗社区提供教育资源，以促进医疗大麻纳入医疗保健方案。</li>
<li><strong>制药管道：</strong> 利用 Avicanna 的科学平台、垂直整合和真实世界证据，Avicanna 开发了一系列专有的、针对特定适应症的基于 cannabinoids 的候选药物，这些药物处于不同的临床开发阶段。这些基于 cannabinoids 的候选药物旨在解决皮肤科、慢性疼痛和各种神经系统疾病等领域的未满足需求。</li>
<li><strong>活性药物成分（Aureus Santa Marta™）：</strong> 由公司控股子公司 Santa Marta Golden Hemp SAS（“SMGH”）提供的活性药物成分是一个商业阶段的业务，致力于为公司的国际合作伙伴提供各种高质量的 CBD、THC 和 CBG，用于食品、化妆品、医疗和制药产品的开发和生产。SMGH 也是公司供应链的一部分，是其全球消费零售、医疗大麻和制药产品可靠的输入产品来源。</li>
</ul>
</div><p><strong>SOURCE Avicanna Inc</strong>.</p>
<div class="lb-trans"><p><strong>来源 Avicanna Inc</strong>。</p>
</div><p><strong>Stay Connected</strong></p>
<div class="lb-trans"><p><strong>保持联系</strong></p>
</div><p>For more information about Avicanna, visit our website or contact Ivana Maric by email at ir@avicanna.com.</p>
<div class="lb-trans"><p>有关 Avicanna 的更多信息，请访问我们的网站或通过电子邮件联系 Ivana Maric，邮箱为 ir@avicanna.com。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Information and Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性信息和声明的警示说明</strong></p>
</div><p>This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements with respect to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2026, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.</p>
<div class="lb-trans"><p>本新闻稿包含适用证券法意义上的 “前瞻性信息”。本新闻稿中包含的前瞻性信息可通过使用 “可能”、“将”、“可以”、“很可能”、“期待”、“预期”、“相信”、“打算”、“计划”、“预测”、“项目”、“估计”、“展望” 等类似表达来识别。新闻稿中包含的前瞻性信息包括但不限于关于公司未来业务运营、管理层的意见或信念以及未来业务目标的声明。尽管公司相信这些前瞻性信息所基于的期望和假设是合理的，但不应过度依赖这些前瞻性信息，因为公司无法保证它们将被证明是正确的。实际结果和发展可能与这些声明所设想的有实质性差异。前瞻性信息受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际事件或结果与前瞻性信息中预测的有实质性差异。这些风险和不确定性包括但不限于当前和未来的市场条件，包括公司普通股的市场价格，以及在公司于 2026 年 3 月 31 日提交给加拿大证券监管机构的年度信息表中列出的风险因素，该信息表可在公司在 SEDAR+ 上的资料中找到，网址为 www.sedarplus.ca。本文中的声明截至本发布之日。公司不承担更新任何前瞻性信息的意图或义务，无论是由于新信息、未来事件或结果，还是其他原因，除非适用证券法要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjd09ERTJNeU0zTlRZNU16YzJJekl5TURFME5qYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcwODE2MyM3NTY5Mzc2IzIyMDE0Njc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGY0N2Y0ZTQtZjIxNy00NTZkLTk2OGMtMWU4ZjM3MGYxZDc5LTEyMTMwMjAtMjAyNi0wNC0yOC1lbg==/tiny/Avicanna-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZGY0N2Y0ZTQtZjIxNy00NTZkLTk2OGMtMWU4ZjM3MGYxZDc5LTEyMTMwMjAtMjAyNi0wNC0yOC1lbg==/tiny/Avicanna-Inc-.png"/></p>

Avicanna 欢迎美国首次重新安排医用大麻的时间表，并提供科学更新 | AVCNF 股票新闻